Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 2/20 | 0.34 |
| ▸ | NADK | O95544 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521224 | 0.92 | POLB (0.46) | STING1POLBFUT5NT5E | |
| SCHEMBL22399438 | 0.92 | POLB (0.46) | STING1POLBFUT5NT5E | |
| SCHEMBL22381585 | 0.88 | POLB (0.45) | STING1POLBFUT5NT5E | |
| SCHEMBL24499633 | 0.86 | NT5E (0.41) | STING1POLBFUT5NT5E | |
| SCHEMBL22381951 | 0.85 | POLB (0.48) | STING1POLBFUT5NT5E | |
| SCHEMBL21943277 | 0.83 | FUT5 (0.41) | STING1POLBFUT5NT5E | |
| SCHEMBL18520927 | 0.83 | STING1 (0.46) | STING1POLBFUT5NT5E | |
| SCHEMBL18520897 | 0.82 | POLB (0.45) | STING1POLBFUT5NT5E | |
| SCHEMBL18521595 | 0.79 | STING1 (0.46) | STING1POLBFUT5NT5E | |
| SCHEMBL21943268 | 0.78 | FUT5 (0.40) | STING1POLBFUT5NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | P2RX3 127/4885TYMP 1508/4885ALDH1A1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.